Loading the company…
Loading the company…
㈜인성제약
English name as filed with DART, Korea’s corporate disclosure system · Correct the English name ›
Last updated 2026-11-02 · Korean page ›
Verification level — how far we have checked
L0 · Public records — NPS workforce · filed financials · patents — public data
A company based in Chungbuk, founded in 2001. Industry: Food & Consumer Goods. Revenue for 2025 was ₩28.6bn. It has 60 employees enrolled in the National Pension Service (as of Aug 2026). It is externally audited; the latest audit opinion is “Unqualified”.
Loading…
Latest filing 2014-08-19 · latest registration 2015-01-23 · newest first
본 발명은 배변촉진용 또는 다이어트용 식품 조성물에 대한 것으로, 더욱 구체적으로는 차전자피 분말; 아스퍼질러스 오리재(Aspergillus oryzae); 및 알로에추출 분말;을 포함하는 것을 특징으로 하여, 식이섬유 소재 중에서 불용성인 차전자피 분말을 상기 아스퍼질러스 오리재에 의하여 발효시킴으로서, 섭취의 용이성을 개선할 수 있을 뿐만 아니라, 분말화 할 수 있고, 발효에 의해 활성 효소물질(아밀라제, 프로테아제, 리파제 등)을 생성하여 음식물의 소화를 돕는 등 체내신진대사를 증진시키며, 알로에 추출 분말을 포함하여 변비와 다이어트, 피로회복, 숙취해소에 유용한 효과를 가진다.
본 발명은 관절보호활성을 유도하는 천연 생약추출물의 제조방법에 관한것으로 천마,황기,동충하초를 주재료로하고 여기에 녹용을 혼합하여 열수추출 또는 알콜, 메탄올 및 에틸에테르 분획 추출하여 제조됨을 특징으로한다. 관절염, 관절활성, 천마, 황기, 동충하초, 녹용
본 발명은 미백기능을 갖는 한방 및 천연물의 혼합추출물에 대한 발명으로서 동의보감, 민간요법 등에서 그 식물안전성이 입증된 꾸지뽕나무, 복분자, 구기자, 녹차, 우롱차, 감초, 매실, 검정쌀, 오이, 배를 일정 비율로 혼합한 혼합물에 대하여 물(증류수), 에탄올수용액, 1,3-부틸렌글리콜수용액 등의 용매를 적용하여 추출한 미백성분을 유효성분으로 하는 혼합추출물을 얻고자 하는 발명이다. 한방소재, 혼합추출물, 꾸지뽕나무, 복분자, 구기자, 녹차, 우롱차, 감초, 매실, 검정쌀, 오이, 배
KIPO KIPRIS · checked 2026-10-15 · newest filings first · right: registration date (filing date if not yet registered) · 3 of 3 · titles and abstracts are in Korean as filed · click a row for details ▾
For now we hold public records only (National Pension Service · DART filings · patents · registers · press). When the company files material in our IR Room, it moves to L1. We do not score or rate companies — we only state how far we have checked.
| KRW bn | 2024 | 2025 |
|---|---|---|
| Revenue | 33.1 | 28.6 |
| Cost of sales | 31.0 | 27.1 |
| Gross profit (loss) | 2.1 | 1.5 |
| Selling, general and administrative expenses | 2.1 | 2.3 |
| Operating income (loss) | 0.0 | (0.8) |
| Non-operating income | 0.3 | 0.4 |
| Other gains | 0.2 | 0.1 |
| Finance income | 0.1 | 0.3 |
| Other | 0.0 | — |
| Non-operating expenses | 0.0 | 0.0 |
| Other losses | 0.0 | 0.0 |
| Finance costs | — | 0.0 |
| Other | 0.0 | — |
| Profit (loss) before tax | 0.4 | (0.4) |
| Income tax expense | 0.0 | 0.0 |
| Net income (loss) | 0.3 | (0.4) |
Revenue ₩28.6bn, down 13.6% YoY.
Operating margin -2.9% (prior 0.1%).
Net income ₩-0.4bn.
Need more than is shown here? Ask for more information — full review report · valuation · executive teaser · IM · competitor analysis · due diligence. Tell us what you need and we will reply by email with scope, cost and timing.
Is this your company?
If anything here is wrong, tell us — we check it against the original and correct it. You do not need to join. If you would like your financials verified and this page completed, that is a separate process.
Headlines and links to public articles only · not checked by us (original ↗) · articles are in Korean — English headlines are our translation; where none is shown, “Read in English ›” opens a machine translation · “Broker view” is a forecast, not reported results · checked 2026-11-06